Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective

Rapid transition to home omalizumab treatment for chronic spontaneous urticaria during the COVID-19 pandemic: A patient perspective

Efforts to reduce non-urgent hospital attendances during the COVID-19 pandemic have been the focus of much attention from healthcare professionals worldwide. In Ireland, due to funding constraints omalizumab is only available for hospital-based administration. Fifty-eight patients with chronic spont...

Full description

Bibliographic Details
Main Authors: Catherine King, Fionnuala Cox, Anne Sloan, Patricia McCrea, J.David Edgar, Niall Conlon
Format: Article
Language:English
Published: Elsevier 2021-10-01
Series:World Allergy Organization Journal
Subjects:
Chronic urticaria
Omalizumab
Self-administration
Patient reported outcome measure
COVID-19
Online Access:http://www.sciencedirect.com/science/article/pii/S1939455121000818

Internet

http://www.sciencedirect.com/science/article/pii/S1939455121000818

Similar Items